Revival of the VEGF ligand family?
作者信息
Niclou Simone P
机构信息
NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg.
Kristian Gerhard Jebsen Brain Tumour Research Center, Department of Biomedicine, University of Bergen, Norway.
出版信息
Neuro Oncol. 2018 Oct 9;20(11):1421-1422. doi: 10.1093/neuonc/noy127.
Abstract
摘要
相似文献
1
Revival of the VEGF ligand family?VEGF配体家族的复苏？
Neuro Oncol. 2018 Oct 9;20(11):1421-1422. doi: 10.1093/neuonc/noy127.
2
VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.VEGF-C 在贝伐珠单抗治疗下维持 VEGFR2 激活，并促进胶质母细胞瘤的维持。
Neuro Oncol. 2018 Oct 9;20(11):1462-1474. doi: 10.1093/neuonc/noy103.
3
Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.阿司匹林影响肿瘤血管生成，并使人类胶质母细胞瘤内皮细胞对替莫唑胺、贝伐单抗和舒尼替尼敏感，损害血管内皮生长因子相关信号传导。
World Neurosurg. 2018 Dec;120:e380-e391. doi: 10.1016/j.wneu.2018.08.080. Epub 2018 Aug 23.
4
Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.血管内皮生长因子A、其受体VEGFR-1、-2和-3以及共受体神经纤毛蛋白-1和-2的差异表达不能预测人星形细胞瘤中贝伐单抗的反应。
Neuro Oncol. 2016 Feb;18(2):173-83. doi: 10.1093/neuonc/nov288. Epub 2015 Nov 30.
5
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.靶向血管内皮生长因子的单克隆抗体：癌症治疗的现状与未来挑战
BioDrugs. 2009;23(5):289-304. doi: 10.2165/11317600-000000000-00000.
6
Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas.VEGF-C和VEGFR-3在胶质母细胞瘤和血管母细胞瘤中的表达及定位
J Pathol. 2006 May;209(1):34-43. doi: 10.1002/path.1943.
7
A case of complete clearance of chronic subdural hematoma accompanied by recurrent glioblastoma multiforme after administration of bevacizumab.1例慢性硬膜下血肿完全清除病例，该患者在使用贝伐单抗后出现复发性多形性胶质母细胞瘤。
Neurosurg Rev. 2016 Jul;39(3):525-9. doi: 10.1007/s10143-016-0704-0. Epub 2016 Feb 26.
8
The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells.抗血管内皮生长因子受体-1 单克隆抗体 D16F7 抑制人脑胶质瘤和脑胶质瘤干细胞的侵袭性。
J Exp Clin Cancer Res. 2017 Aug 10;36(1):106. doi: 10.1186/s13046-017-0577-2.
9
Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma.MET与VEGF抑制剂联合治疗MET过表达胶质母细胞瘤的疗效
Anticancer Res. 2017 Jul;37(7):3871-3876. doi: 10.21873/anticanres.11767.
10
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.舒尼替尼在贝伐单抗难治性转移性肾细胞癌患者中的抗肿瘤活性及生物标志物分析
J Clin Oncol. 2008 Aug 1;26(22):3743-8. doi: 10.1200/JCO.2007.15.5416.
引用本文的文献
1
CR13626: a novel oral brain penetrant tyrosine kinase inhibitor that reduces tumor growth and prolongs survival in a mouse model of glioblastoma.CR13626：一种新型口服脑渗透性酪氨酸激酶抑制剂，可在胶质母细胞瘤小鼠模型中减少肿瘤生长并延长生存期。
Am J Cancer Res. 2021 Jul 15;11(7):3558-3574. eCollection 2021.
2
Rational Design of Antiangiogenic Helical Oligopeptides Targeting the Vascular Endothelial Growth Factor Receptors.靶向血管内皮生长因子受体的抗血管生成螺旋寡肽的合理设计
Front Chem. 2019 Mar 29;7:170. doi: 10.3389/fchem.2019.00170. eCollection 2019.
本文引用的文献
1
VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.VEGF-C 在贝伐珠单抗治疗下维持 VEGFR2 激活，并促进胶质母细胞瘤的维持。
Neuro Oncol. 2018 Oct 9;20(11):1462-1474. doi: 10.1093/neuonc/noy103.
2
Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma.抗血管生成治疗后胶质母细胞瘤肿瘤血管功能未正常化。
J Cereb Blood Flow Metab. 2018 Oct;38(10):1741-1753. doi: 10.1177/0271678X17714656. Epub 2017 Jun 19.
3
Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials.抗血管生成药物治疗胶质母细胞瘤患者的疗效：系统评价和随机临床试验荟萃分析。
Crit Rev Oncol Hematol. 2017 Mar;111:94-102. doi: 10.1016/j.critrevonc.2017.01.018. Epub 2017 Jan 30.
4
Mechanisms and regulation of endothelial VEGF receptor signalling.内皮细胞 VEGF 受体信号转导的机制和调控。
Nat Rev Mol Cell Biol. 2016 Oct;17(10):611-25. doi: 10.1038/nrm.2016.87. Epub 2016 Jul 27.
5
Current status and future directions of anti-angiogenic therapy for gliomas.神经胶质瘤抗血管生成治疗的现状与未来方向
Neuro Oncol. 2016 Mar;18(3):315-28. doi: 10.1093/neuonc/nov180. Epub 2015 Oct 12.
6
The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis.细胞对血管内皮生长因子的反应需要协调的信号转导、运输和蛋白水解作用。
Biosci Rep. 2015 Aug 18;35(5):e00253. doi: 10.1042/BSR20150171.
7
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.西地尼布联合放化疗后血供增加的胶质母细胞瘤患者的肿瘤氧合和生存改善。
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19059-64. doi: 10.1073/pnas.1318022110. Epub 2013 Nov 4.
8
An inside view: VEGF receptor trafficking and signaling.内幕观察：VEGF 受体运输和信号转导。
Physiology (Bethesda). 2012 Aug;27(4):213-22. doi: 10.1152/physiol.00016.2012.
9
Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth.自分泌 VEGF-VEGFR2-神经纤毛蛋白-1 信号促进神经胶质瘤干细胞样细胞的活力和肿瘤生长。
J Exp Med. 2012 Mar 12;209(3):507-20. doi: 10.1084/jem.20111424. Epub 2012 Mar 5.
10
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.舒尼替尼对人胶质母细胞瘤实验模型的抗血管生成和抗侵袭作用
Neuro Oncol. 2007 Oct;9(4):412-23. doi: 10.1215/15228517-2007-024. Epub 2007 Jul 10.
Zotero 插件